38384296|t|Esketamine combined with sufentanil versus sufentanil in patient-controlled intravenous analgesia: a meta-analysis.
38384296|a|Objective: Patient-controlled intravenous analgesia (PCIA) can alleviate pain to some extent, and several randomized controlled trials (RCTs) have examined the efficacy of esketamine-assisted sufentanil in postoperative PCIA. In this research, we conducted a meta-analysis of relevant RCTs to compare the effect and safety of esketamine-sufentanil versus sufentanil alone for postoperative PCIA. Methods: We systematically searched the Cochrane Library, PubMed, Embase, Web of Science, CNKI, and other libraries up to December 2023 to screen out RCTs examining the use of esketamine combined with sufentanil for PCIA. We analysed analgesia scores, sedation scores, adverse drug reactions and postpartum depression scores as outcome indicators. Results: This meta-analysis included 32 RCTs. The results of the meta-analysis were as follows. 1) Visual Analog Scale: The VAS scores at 6, 12, 24, and 48 h were lower in the esketamine-sufentanil group than in the sufentanil alone group, and significant differences were found at all time points (p < 0.05). 2) Ramsay Sedation Scale: The sedation score of the esketamine-sufentanil group at 48 h after surgery was higher than that of the sufentanil group alone [mean difference (MD) = -0.09 points, confidence interval (CI): (-0.26, -0.07), p = 0.27], but this difference was not significant (p > 0.05). 3) Safety: Compared with sufentanil alone, the incidence rates of postoperative nausea-vomiting, dizziness-headache, skin pruritus and respiratory depression were significantly lower in the esketamine-sufentanil group. 4) Postartum depression: The reduction in postpartum depression scores were significantly greater in the esketamine-sufentanil group than in the sufentanil alone group at 3 days [MD = -1.35 points, CI: (-1.89, -0.81), p < 0.00001] and 7 days [MD = -1.29 points, CI: (-2.42, -0.16), p = 0.03]. Conclusion: The meta-analysis showed that the use of esketamine combined with sufentanil for postoperative PCIA could improve postoperative analgesia, alleviate postpartum depression and reduce the rate of postoperative adverse reactions, but there was no significant difference in sedation.
38384296	0	10	Esketamine	Chemical	MESH:C000629870
38384296	25	35	sufentanil	Chemical	MESH:D017409
38384296	43	53	sufentanil	Chemical	MESH:D017409
38384296	57	64	patient	Species	9606
38384296	127	134	Patient	Species	9606
38384296	169	173	PCIA	Disease	MESH:D000699
38384296	189	193	pain	Disease	MESH:D010146
38384296	288	298	esketamine	Chemical	MESH:C000629870
38384296	308	318	sufentanil	Chemical	MESH:D017409
38384296	336	340	PCIA	Disease	MESH:D000699
38384296	442	452	esketamine	Chemical	MESH:C000629870
38384296	453	463	sufentanil	Chemical	MESH:D017409
38384296	471	481	sufentanil	Chemical	MESH:D017409
38384296	506	510	PCIA	Disease	MESH:D000699
38384296	688	698	esketamine	Chemical	MESH:C000629870
38384296	713	723	sufentanil	Chemical	MESH:D017409
38384296	728	732	PCIA	Disease	MESH:D000699
38384296	781	803	adverse drug reactions	Disease	MESH:D064420
38384296	808	829	postpartum depression	Disease	MESH:D019052
38384296	1036	1046	esketamine	Chemical	MESH:C000629870
38384296	1047	1057	sufentanil	Chemical	MESH:D017409
38384296	1076	1086	sufentanil	Chemical	MESH:D017409
38384296	1222	1232	esketamine	Chemical	MESH:C000629870
38384296	1233	1243	sufentanil	Chemical	MESH:D017409
38384296	1300	1310	sufentanil	Chemical	MESH:D017409
38384296	1491	1501	sufentanil	Chemical	MESH:D017409
38384296	1532	1561	postoperative nausea-vomiting	Disease	MESH:D020250
38384296	1563	1572	dizziness	Disease	MESH:D004244
38384296	1573	1581	headache	Disease	MESH:D006261
38384296	1583	1596	skin pruritus	Disease	MESH:D011537
38384296	1601	1623	respiratory depression	Disease	MESH:D012131
38384296	1656	1666	esketamine	Chemical	MESH:C000629870
38384296	1667	1677	sufentanil	Chemical	MESH:D017409
38384296	1698	1708	depression	Disease	MESH:D003866
38384296	1727	1748	postpartum depression	Disease	MESH:D019052
38384296	1790	1800	esketamine	Chemical	MESH:C000629870
38384296	1801	1811	sufentanil	Chemical	MESH:D017409
38384296	1830	1840	sufentanil	Chemical	MESH:D017409
38384296	2031	2041	esketamine	Chemical	MESH:C000629870
38384296	2056	2066	sufentanil	Chemical	MESH:D017409
38384296	2085	2089	PCIA	Disease	MESH:D000699
38384296	2139	2160	postpartum depression	Disease	MESH:D019052
38384296	2184	2215	postoperative adverse reactions	Disease	MESH:D064420
38384296	Positive_Correlation	MESH:D017409	MESH:D011537
38384296	Negative_Correlation	MESH:C000629870	MESH:D004244
38384296	Negative_Correlation	MESH:C000629870	MESH:D006261
38384296	Negative_Correlation	MESH:C000629870	MESH:D012131
38384296	Negative_Correlation	MESH:C000629870	MESH:D003866
38384296	Negative_Correlation	MESH:C000629870	MESH:D011537
38384296	Positive_Correlation	MESH:D017409	MESH:D006261
38384296	Negative_Correlation	MESH:D017409	MESH:D000699
38384296	Negative_Correlation	MESH:C000629870	MESH:D020250
38384296	Negative_Correlation	MESH:C000629870	MESH:D000699
38384296	Negative_Correlation	MESH:C000629870	MESH:D019052
38384296	Positive_Correlation	MESH:D017409	MESH:D020250
38384296	Positive_Correlation	MESH:D017409	MESH:D004244
38384296	Cotreatment	MESH:C000629870	MESH:D017409
38384296	Positive_Correlation	MESH:D017409	MESH:D012131

